Test Price
2,800 AED✅ Home Collection Available
RIT1 Gene Noonan Syndrome Type 8 Genetic Test | DNA Labs UAE
Executive Summary & Core Metrics
This advanced molecular diagnostic assay provides definitive genetic analysis of the RIT1 gene via next-generation sequencing, facilitating accurate diagnosis of Noonan Syndrome Type 8. The test is offered exclusively by DNA Labs UAE under DHA Facility License 1143, ensuring full regulatory compliance and clinical integrity within the Dubai Healthcare City jurisdiction.
- ✓ Diagnostic Precision: >99.9% analytical sensitivity and specificity via ISO 15189 accredited NGS workflow with orthogonal confirmation.
- ✓ Integrated Logistics: Complimentary VIP mobile phlebotomy and temperature-controlled cold-chain home collection, available daily from 8 AM to 11 PM.
- ✓ Clinical Governance: Results are reviewed and authorized by our Consultant Medical Genetics team, with mandatory pre- and post-test genetic counselling included.
- ✓ Insurance & Billing: Direct billing verification and price lock guarantee at 2,800 AED. Contact via WhatsApp at +971 54 548 8731 for rapid eligibility confirmation.
Test Overview & Methodology
The RIT1 Gene Noonan Syndrome Type 8 Genetic Test employs targeted next-generation sequencing (NGS) to detect pathogenic single-nucleotide variants and small insertions or deletions within the coding exons and flanking intronic regions of the RIT1 gene. RIT1-associated Noonan syndrome is an autosomal dominant RASopathy clinically characterized by distinctive facial features, congenital heart defects (most commonly hypertrophic cardiomyopathy and pulmonic stenosis), short stature, and an elevated lifetime risk for juvenile myelomonocytic leukemia. Molecular confirmation of a RIT1 variant enables precise clinical management, including tailored cardiac surveillance, growth hormone therapy evaluation, and family cascade screening.
| Feature | DNA Labs UAE Premium DHA Service | Closest Alternative |
|---|---|---|
| Analytical Precision | Full gene NGS with >99.9% sensitivity, including deep intronic coverage and CNV detection | Targeted Sanger sequencing or restricted panel, missing deep intronic and structural variants |
| Platform & Accreditation | Illumina® NextSeq 550 system operating under ISO 15189 and CAP accreditation frameworks | Non-accredited research-grade PCR or Sanger sequencing without validated SOPs |
| Turnaround Time | 21–28 business days with secure online portal tracking and automated status updates | 6–10 weeks with intermittent manual communication |
| Specimen Collection | VIP mobile phlebotomy and cold-chain courier service; FTA card option available | Clinic-only draw or uncontrolled ambient shipping |
| Post-Test Support | Mandatory telephonic clinical guidance and genetic counselling session with report delivery | Written report only; no structured counselling follow-up |
All prices are inclusive of DHA-mandated reporting and genetic counselling. Price may vary for comprehensive family segregation studies.
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “The RIT1 NGS assay provides definitive molecular evidence for a clinical diagnosis of Noonan syndrome type 8. However, a genetic finding must always be integrated with the full phenotypic assessment. A positive result confirms the molecular etiology but does not in itself define disease trajectory, severity, or optimal therapeutic window. I strongly advise that all patients and families undergo structured pre-test genetic counselling to address the implications for reproductive planning and at-risk relatives. Molecular data empowers precision care, but only when contextualized within a comprehensive clinical framework.”
Pharmacologic & Clinical Advisory
Do not alter, suspend, or discontinue any prescribed medication—including growth hormone therapy, beta-blockers, or anticoagulants—without direct authorization from your managing specialist. This genetic report is an adjunctive diagnostic instrument and does not supersede clinical judgment. If the patient experiences new-onset dyspnea, syncope, chest pain, or unexplained fever with petechiae, proceed immediately to the nearest emergency department.
Safety & Sample Exclusion Criteria
- Hematologic Contamination: Allogeneic blood transfusion or stem cell infusion within 4 weeks prior to collection—donor DNA chimerism may invalidate germline analysis.
- Consent & Legal Guardianship: Absence of signed informed consent; for minors, consent must be provided by a legal guardian and witnessed per DHA regulatory standards and Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Insufficient Biological Material: Inability to provide a minimum of 2 mL of whole blood in an EDTA Vacutainer® or a properly desiccated FTA card with a visible blood spot.
- Active Hematologic Malignancy: Circulating blasts or malignant clones may interfere with variant allele frequency interpretation.
Patient FAQ & Clinical Guidance
1. What is the RIT1 Gene Noonan Syndrome Type 8 Genetic Test?
This is a clinical grade next-generation sequencing test that examines the entire coding sequence of the RIT1 gene. It is designed to identify disease-causing mutations responsible for Noonan Syndrome Type 8, a congenital disorder affecting the RAS-MAPK signaling pathway, which leads to characteristic cardiac, craniofacial, and growth abnormalities.
2. How is the sample collected for this genetic test?
A certified and experienced phlebotomist will perform a peripheral venipuncture to collect 2–3 mL of whole blood into an EDTA tube. Alternatively, a single drop of blood can be placed on an FTA card. Our VIP mobile phlebotomy service brings this directly to your home, with temperature-controlled transport ensuring nucleic acid integrity.
3. When will I receive my RIT1 results?
Results are finalized within 21 to 28 business days from the date the specimen is received by our laboratory. You will receive a comprehensive, DHA-compliant PDF report via a secure encrypted portal, followed by a mandatory telephonic interpretation session with a member of our Clinical Genetics team.
4. Will my health insurance cover the 2,800 AED cost?
Coverage varies by insurance provider and plan. DNA Labs UAE offers a direct billing verification service—simply forward your policy details and coverage inquiry via WhatsApp to +971 54 548 8731, and our billing team will secure a real-time eligibility response within 2 business hours.
5. What does the mandatory genetic counselling involve?
Pre-test counselling explains the scope of the analysis, potential incidental findings, and the implications for family members. Post-test counselling systematically reviews your report, clarifies variant classification, and provides evidence-based recommendations for clinical surveillance and family cascade testing, ensuring you are fully informed at every stage of the diagnostic process.
UAE Regulatory & Data Privacy Adherence
Federally Mandated Data Protection & Health Information Governance
DNA Labs UAE strictly adheres to the UAE’s comprehensive federal data protection landscape. All personal genetic and health data processed during the RIT1 assay are safeguarded under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), which governs the collection, processing, and storage of sensitive personal data. Furthermore, our health information systems and clinical data handling protocols are fully compliant with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring that your genomic data is protected by the highest standards of encryption, access control, and audit trail transparency.
Our laboratory operates exclusively under DHA Facility License 1143 and is subject to periodic inspection and quality audits by the Dubai Health Authority. Patient data is never shared with third parties without explicit, informed consent, except where required by UAE federal law for public health reporting.
Clinical & Logistical Metadata
| Test Name | RIT1 Gene Noonan Syndrome Type 8 NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Business Days |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | Q87.1 |
| LOINC Code | 81321-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians